Wegovy’s supply + brewing competition concerns overshadow a decent Q2
04/08/22 -"In Q2, Novo continued its strong run, driven by strong growth momentum seen in both Obesity and GLP-1 Diabetes franchise. However, emerging and potential competition from Eli Lilly’s Mounjaro in ..."
Pages
72
Language
English
Published on
04/08/22
You may also be interested by these reports :
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum
20/08/25
Following Donald Trump’s tariff threats and given the generic/biosimilar medicine makers’ relatively thin profitability, the markets were quick to ...